Huonslab

About Huonslab

Huonslab, a Korean biotech, specializes in bio R&D. Its flagship platform, HyDIFFUZE technology (rHuPH20 stand-alone), which facilitates IV to SC administration conversion. Huonslab is supported by its parent company, Huons Global, which boasts $586M revenue and a 19% 19Y-CAGR in 2023, along with a 60-year legacy in the healthcare industry.

  • KR
  • 2024
    On CPHI since
  • 1 - 24
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Contact info
  • 14, galmachi-ro 288beon-gil,, 13201, Seongnam-si, Korea, Republic Of

Products from Huonslab (1)

  • Recombinant Human Hyaluronidase PH20 (rHuPH20) - HyDIFFUZE TM

    Product Recombinant Human Hyaluronidase PH20 (rHuPH20) - HyDIFFUZE TM

    Hyaluronidase, an enzyme that breaks down hyaluronic acid, facilitates the dispersion and absorption of co-administered drug in the subcutaneous space. This enables a conversion of administration route from IV to SC.

    Recombinant Human hyaluronidase PH20 (rHuPH20), a human tes...